Fig. 2: CXCL11 mediates anlotinib inhibition of hypoxia-activated angiogenesis. | British Journal of Cancer

Fig. 2: CXCL11 mediates anlotinib inhibition of hypoxia-activated angiogenesis.

From: The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis

Fig. 2

a Heatmap of the molecular changes from the angiogenesis antibody array, which was performed under hypoxia (2% concentration of O2). b The CXCL11 production under hypoxia or anlotinib treatment in CAL-62 and KHM-5M cells. c–e Addition of rhCXCL11 into the supernatants from CAL-62 and KHM-5M cells treated with anlotinib could reverse anlotinib’s anti-angiogenic abilities; adding CXCL11 neutralise antibody into the supernatants from CAL-62 and KHM-5M cells treated with hypoxia could partly attenuate hypoxia-induced angiogenesis. Angiogenic assays included tubule formation (c), HUVEC migration (d) and HUVEC proliferation (e). All data are obtained from three independent experiments. *P < 0.05; **P < 0.01.

Back to article page